Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASFRA:A71 +0.98%37 Cyclically Adjusted PB Ratio is 29.81 as of Aug. 04, 2026, which is 5% above its 10-year median of 28.50. GuruFocus rates FRA:A71 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 697 Biotechnology companies, Ascendis Pharma AS ranks worse than 96.7% on this metric.
The historical rank and industry rank for Ascendis Pharma AS's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:A71'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 24.93 Med: 28.5 Max: 32.52
Current: 28.91
During the past years, Ascendis Pharma AS's highest Cyclically Adjusted PB Ratio was 32.52. The lowest was 24.93. And the median was 28.50.
FRA:A71's Cyclically Adjusted PB Ratio is ranked worse than 96.7% of 697
companies
in the Biotechnology industry
Industry Median: 1.6
vs FRA:A71: 28.91
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Ascendis Pharma AS's adjusted book value per share data for the three months ended in Mar. 2026 was €7.948. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.91 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Ascendis Pharma AS (FRA:A71) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Ascendis Pharma AS Cyclically Adjusted PB Ratio Related Terms
Ascendis Pharma AS Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS Cyclically Adjusted PB Ratio Chart
FRA:A71 vs BBIO, JAZZ, EXEL: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PB Ratio falls into.
Ascendis Pharma AS Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Ascendis Pharma AS's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 29.81 mean?
Ascendis Pharma AS (FRA:A71) has a Cyclically Adjusted PB Ratio of 29.81 as of Aug. 04, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. This is near median its historical median of 28.50. Over the past decade, Ascendis Pharma AS's Cyclically Adjusted PB Ratio has ranged from 24.93 to 32.52. According to the industry distribution chart, Ascendis Pharma AS ranks #674 out of 697 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Ascendis Pharma AS's Cyclically Adjusted PB Ratio too high?
Ascendis Pharma AS's current Cyclically Adjusted PB Ratio of 29.81 is near median its 10-year median of 28.50. Over the past 10 years, this metric has ranged from a low of 24.93 to a high of 32.52. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.60. Ascendis Pharma AS's value of 29.81 is 1763.1% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #674 out of 697 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Cyclically Adjusted PB Ratio compare to BBIO and JAZZ?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #674 out of 697 companies for Cyclically Adjusted PB Ratio. This places Ascendis Pharma AS in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.60. Ascendis Pharma AS's value of 29.81 is 1763.1% above this benchmark. Historically, Ascendis Pharma AS's own Cyclically Adjusted PB Ratio has ranged from 24.93 to 32.52 over the past decade. While the company's 10-year median is 28.50 vs. the industry median of 1.60, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.60, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Cyclically Adjusted PB Ratio of 29.81 is 1763.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Cyclically Adjusted PB Ratio is 29.81, which is near median its own 10-year median of 28.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (FRA:A71) has a current Cyclically Adjusted PB Ratio of 29.81. The current Cyclically Adjusted PB Ratio is 29.81, which is near median its 10-year median of 28.50 and 1763.1% above the Biotechnology industry median of 1.60. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Ascendis Pharma AS (FRA:A71), the current Cyclically Adjusted PB Ratio is 29.81 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for FRA:A71
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A71 has been successfully added to your 
